vs
CareDx, Inc.（CDNA）与MARCUS CORP（MCS）财务数据对比。点击上方公司名可切换其他公司
MARCUS CORP的季度营收约是CareDx, Inc.的1.6倍（$193.5M vs $117.7M），CareDx, Inc.同比增速更快（39.0% vs 2.8%），MARCUS CORP自由现金流更多（$26.4M vs $514.0K），过去两年MARCUS CORP的营收复合增速更高（18.2% vs 12.9%）
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
马库斯公司是一家美国企业，主营商业地产领域相关服务，业务覆盖美国与加拿大，提供商业地产经纪、按揭经纪、行业研究以及咨询服务，首创了由单一经纪公司独家代理房源挂牌的行业模式，目前在美加两国设有超过80家办公室，拥有员工超1800名。
CDNA vs MCS — 直观对比
营收规模更大
MCS
是对方的1.6倍
$117.7M
营收增速更快
CDNA
高出36.2%
2.8%
自由现金流更多
MCS
多$25.9M
$514.0K
两年增速更快
MCS
近两年复合增速
12.9%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $117.7M | $193.5M |
| 净利润 | $2.8M | — |
| 毛利率 | — | — |
| 营业利润率 | 1.0% | 0.9% |
| 净利率 | 2.4% | — |
| 营收同比 | 39.0% | 2.8% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.05 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDNAMCS
| Q1 26 | $117.7M | — | ||
| Q4 25 | $108.4M | $193.5M | ||
| Q3 25 | $100.1M | $210.2M | ||
| Q2 25 | $86.7M | $206.0M | ||
| Q1 25 | $84.7M | $148.8M | ||
| Q4 24 | $86.6M | $188.3M | ||
| Q3 24 | $82.9M | $232.7M | ||
| Q2 24 | $92.3M | $176.0M |
净利润CDNAMCS
| Q1 26 | $2.8M | — | ||
| Q4 25 | $-4.1M | — | ||
| Q3 25 | $1.7M | $16.2M | ||
| Q2 25 | $-8.6M | $7.3M | ||
| Q1 25 | $-10.4M | $-16.8M | ||
| Q4 24 | $87.7M | $986.0K | ||
| Q3 24 | $-10.6M | $23.3M | ||
| Q2 24 | $-4.6M | $-20.2M |
营业利润率CDNAMCS
| Q1 26 | 1.0% | — | ||
| Q4 25 | -5.6% | 0.9% | ||
| Q3 25 | -0.2% | 10.8% | ||
| Q2 25 | -12.8% | 6.3% | ||
| Q1 25 | -15.8% | -13.7% | ||
| Q4 24 | 97.5% | -1.2% | ||
| Q3 24 | -16.6% | 14.1% | ||
| Q2 24 | -7.9% | 1.3% |
净利率CDNAMCS
| Q1 26 | 2.4% | — | ||
| Q4 25 | -3.8% | — | ||
| Q3 25 | 1.7% | 7.7% | ||
| Q2 25 | -9.9% | 3.6% | ||
| Q1 25 | -12.2% | -11.3% | ||
| Q4 24 | 101.3% | 0.5% | ||
| Q3 24 | -12.8% | 10.0% | ||
| Q2 24 | -5.0% | -11.5% |
每股收益（稀释后）CDNAMCS
| Q1 26 | $0.05 | — | ||
| Q4 25 | $-0.08 | — | ||
| Q3 25 | $0.03 | — | ||
| Q2 25 | $-0.16 | — | ||
| Q1 25 | $-0.19 | — | ||
| Q4 24 | $1.60 | — | ||
| Q3 24 | $-0.20 | — | ||
| Q2 24 | $-0.09 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.9M | $23.4M |
| 总债务越低越好 | — | $159.0M |
| 股东权益账面价值 | — | $457.4M |
| 总资产 | $411.1M | $1.0B |
| 负债/权益比越低杠杆越低 | — | 0.35× |
8季度趋势，按日历期对齐
现金及短期投资CDNAMCS
| Q1 26 | $77.9M | — | ||
| Q4 25 | $177.2M | $23.4M | ||
| Q3 25 | $194.2M | $7.4M | ||
| Q2 25 | $186.3M | $14.9M | ||
| Q1 25 | $230.9M | $11.9M | ||
| Q4 24 | $260.7M | $40.8M | ||
| Q3 24 | $240.9M | $28.4M | ||
| Q2 24 | $228.9M | $32.8M |
总债务CDNAMCS
| Q1 26 | — | — | ||
| Q4 25 | — | $159.0M | ||
| Q3 25 | — | $162.0M | ||
| Q2 25 | — | $179.9M | ||
| Q1 25 | — | $198.9M | ||
| Q4 24 | — | $159.1M | ||
| Q3 24 | $0 | $173.1M | ||
| Q2 24 | $0 | $175.7M |
股东权益CDNAMCS
| Q1 26 | — | — | ||
| Q4 25 | $303.1M | $457.4M | ||
| Q3 25 | $311.1M | $454.3M | ||
| Q2 25 | $327.4M | $448.4M | ||
| Q1 25 | $379.3M | $441.8M | ||
| Q4 24 | $378.4M | $464.9M | ||
| Q3 24 | $273.2M | $462.3M | ||
| Q2 24 | $264.7M | $449.4M |
总资产CDNAMCS
| Q1 26 | $411.1M | — | ||
| Q4 25 | $413.2M | $1.0B | ||
| Q3 25 | $432.3M | $1.0B | ||
| Q2 25 | $444.3M | $1.0B | ||
| Q1 25 | $489.6M | $1.0B | ||
| Q4 24 | $491.1M | $1.0B | ||
| Q3 24 | $477.0M | $1.0B | ||
| Q2 24 | $466.8M | $1.1B |
负债/权益比CDNAMCS
| Q1 26 | — | — | ||
| Q4 25 | — | 0.35× | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.34× | ||
| Q3 24 | 0.00× | 0.37× | ||
| Q2 24 | 0.00× | 0.39× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.3M | $48.8M |
| 自由现金流经营现金流 - 资本支出 | $514.0K | $26.4M |
| 自由现金流率自由现金流/营收 | 0.4% | 13.6% |
| 资本支出强度资本支出/营收 | — | 11.6% |
| 现金转化率经营现金流/净利润 | 1.54× | — |
| 过去12个月自由现金流最近4个季度 | — | $989.0K |
8季度趋势，按日历期对齐
经营现金流CDNAMCS
| Q1 26 | $4.3M | — | ||
| Q4 25 | $21.4M | $48.8M | ||
| Q3 25 | $37.4M | $39.1M | ||
| Q2 25 | $9.9M | $31.6M | ||
| Q1 25 | $-26.6M | $-35.3M | ||
| Q4 24 | $21.9M | $52.6M | ||
| Q3 24 | $12.5M | $30.5M | ||
| Q2 24 | $18.9M | $36.0M |
自由现金流CDNAMCS
| Q1 26 | $514.0K | — | ||
| Q4 25 | — | $26.4M | ||
| Q3 25 | — | $18.2M | ||
| Q2 25 | — | $14.7M | ||
| Q1 25 | — | $-58.3M | ||
| Q4 24 | — | $27.1M | ||
| Q3 24 | — | $12.0M | ||
| Q2 24 | — | $16.1M |
自由现金流率CDNAMCS
| Q1 26 | 0.4% | — | ||
| Q4 25 | — | 13.6% | ||
| Q3 25 | — | 8.7% | ||
| Q2 25 | — | 7.1% | ||
| Q1 25 | — | -39.2% | ||
| Q4 24 | — | 14.4% | ||
| Q3 24 | — | 5.2% | ||
| Q2 24 | — | 9.2% |
资本支出强度CDNAMCS
| Q1 26 | — | — | ||
| Q4 25 | — | 11.6% | ||
| Q3 25 | — | 9.9% | ||
| Q2 25 | — | 8.2% | ||
| Q1 25 | — | 15.5% | ||
| Q4 24 | — | 13.5% | ||
| Q3 24 | — | 7.9% | ||
| Q2 24 | — | 11.3% |
现金转化率CDNAMCS
| Q1 26 | 1.54× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 22.30× | 2.41× | ||
| Q2 25 | — | 4.32× | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.25× | 53.31× | ||
| Q3 24 | — | 1.31× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDNA
| Financial Results Total | $85.0M | 72% |
| Patient and digital solutions revenue | $16.0M | 14% |
| Product revenue | $10.3M | 9% |
| Other | $6.4M | 5% |
MCS
| Theatres | $123.1M | 64% |
| Concessions | $51.0M | 26% |
| Food And Beverage | $21.2M | 11% |
